文献速递抗栓抗凝管理药物不良反应与药物警戒

房颤患者使用VKA、NOAC与阿司匹林的大出血和卒中风险:队列研究

Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study.
PubMed 文献 · Br J Clin Pharmacol · 2017-03-24

结果显示NOAC较VKA大出血风险升高(HR 2.07),主要来自消化道出血且集中于女性;NOAC与VKA预防缺血性卒中效果相当,阿司匹林卒中预防效果劣于VKA。

要点

  • NOAC较VKA大出血风险升高,主要为消化道出血,且集中于女性。
  • NOAC与VKA预防缺血性卒中的效果相当。
  • 阿司匹林不能有效预防房颤患者卒中,且出血风险与VKA相似。

核心结论

  • NOAC与较高的消化道出血风险相关,尤其在女性中,对出血风险高的患者使用NOAC应谨慎考虑。
  • NOAC与VKA预防卒中的效果相当,阿司匹林对房颤患者卒中预防无效。

研究设计与样本

  • 随访从首次处方抗血栓药物开始,至发生卒中或大出血为止,采用Cox回归分析并校正合并症史和用药史。

主要发现

  • NOAC较VKA大出血的HR为2.07(95%CI 1.27-3.38)。
  • 消化道出血风险升高,HR为2.63(95%CI 1.50-4.62)。
  • 出血风险升高仅见于女性,HR为3.14(95%CI 1.76-5.60)。
  • 阿司匹林出血风险与VKA相似。
  • NOAC预防缺血性卒中的HR为1.22(95%CI 0.67-2.19),VKA优于阿司匹林(HR 2.18,95%CI 1.83-2.59)。

临床怎么用

  • 对消化道出血风险高的房颤患者(尤其女性)选用NOAC时应审慎评估。
  • 房颤卒中预防不应以阿司匹林替代抗凝治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Nonvitamin K antagonist oral anticoagulants (NOACs) are now available for the prevention of stroke in patients with atrial fibrillation (AF) as an alternative to vitamin K antagonists (VKA) and aspirin. The comparative effectiveness and safety in daily practice of these different drug classes is still unclear. The objective of this study was to evaluate the risk of major bleeding and stroke in AF patients using NOACs, VKAs or aspirin. METHODS: A retrospective cohort study was conducted among AF patients using the UK Clinical Practice Research Datalink (March 2008-October 2014). New users of VKAs, NOACs and low dose aspirin were followed from the date of first prescription of an antithrombotic drug until the occurrence of stroke or major bleeding. Analyses were adjusted for a history of comorbidities and drug use with Cox regression analysis. RESULTS: A total of 31 497 patients were eligible for the study. The hazard ratio (HR) of major bleeding was 2.07 [95% confidence interval (CI) 1.27-3.38] for NOACs compared with VKAs, which was mainly attributed by the increased risk of gastrointestinal bleeding (HR 2.63, 95% CI 1.50-4.62). This increased bleeding risk was restricted to women (HR 3.14, 95% CI 1.76-5.60). Aspirin showed a similar bleeding risk as VKAs. NOACs showed equal effectiveness as VKA in preventing ischaemic stroke (HR 1.22, 95% CI 0.67-2.19). VKAs were more effective than aspirin (HR 2.18, 95% CI 1.83-2.59). CONCLUSIONS: NOACs were associated with a higher risk on gastrointestinal bleeding, particularly in women. The use of NOACs in patients who are vulnerable for this type of bleeding should be carefully considered. NOACs and VKAs are equally effective in preventing stroke. Aspirin was not effective in the prevention of stroke in AF.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Gieling EM, van den Ham HA, van Onzenoort H, et al. Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. Br J Clin Pharmacol. 2017. PMID: 28205318. doi:10.1111/bcp.13265

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。